



Expr Mail No.: EL 501 639 249 US

Sheet <u>1</u> of <u>1</u>

JUN 2 6 2001 JECH CENTER 1600/2900

	923) - • · ·	<u>.</u> <u>-</u>		ATTY, DOCKET NO.			APPLICATION NO).	
						8449-134			09/750,972		
LIST OF REFERENCES CITED BY APPLICANT						APPLICANT					
		(Use several sheets if n	ecessary)			Srivastava, Pramo	d K.			_	
						FILING DATE			GROUP		
						12/28/00			1645		
			U.S	S. PATENT	DOCUM	ENTS			·		
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE			NAME		CLASS	SUBCLASS	FILIN	G DATE ROPRIATE
										6/2/00	
			FORE	IGN PATEN	IT DOC	UMENTS					
		DOCUMENT NUMBER	DATE	COUNT		COUNTRY		CLASS	SUBCLASS	TRANSLATION	
						· · · · · · · · · · · · · · · · · · ·				YES	NO
CY	DK	WO 94/14976	7/7/94	PCT							
cY	DL	WO 99/50303	10/7/99	РСТ	 						<u> </u>
		OTHER RE	FERENCES (Ir	ncluding Aut	hor, Title	e, Date, Pertinent Pa	ages, Etc.)				
EXAMINER Christyh HX					DATE (CONSIDERED	5/23/	٥٦			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

Sheet<u>1</u> f<u>2</u>



ATTY, DOCKET NO.	APPLICATION NO.
8449-134-999	09/750,972
APPLICANT	
Srivastava, Pramod K.	
FILING DATE	GROUP

SUPPLEMENTAL LIST OF REFERENCES CITED BY APPLICANT

APPLICANT					Srivastava, Pramod K.							
(Use several sheets if necessary)					FILING DATE GROUP 12/28/00 1645							
		_	U.S	S. PATENT DOCUM	ENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
64	DM	5,968,526	10/19/99					6/07/95				
27	DN	US 2002/0001841 A1	1/03/02				6/25/99					
24	DO	6,156,311	12/05/00		·			7/26/96				
			FORE	IGN PATENT DOC	JMENTS							
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANS	NO			
24	DP	WO 00/38760	7/6/00	PCT								
CY	DQ	WO 00/03003	1/20/00	PCT		<u> </u>						
CY	DR	WO 98/42752	10/01/98	PCT								
CY	DS	WO 00/34494	6/15/00	РСТ	•	<u> </u>						
CY	DT	WO 98/46739	7/23/97	PCT		<u> </u>			X			
Ct	DU	WO 97/04794	2/13/97	PCT		<u> </u>		:				
72	DV	WO 00/46246	8/10/00	PCT								
<u> </u>		OTHER RE	FERENCES (In	cluding Author, Title	e, Date, Pertinent Pages, Etc.)							
Agostoni et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.												
۲2	DX	Bednar et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.										
et	DY	Collen et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.										
ct	DZ	Hanover et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.										
23	EA	Hertz et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.										
ct	ЕВ	Hey et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.										
ct	EC	Horn et al., 1995, "Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library", J. of Biol. Chem. 270 (20): 11770-11775.										
c	ED	Huang et al., 1996, "The immunodominant major histocompatability complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product", Proc. Natl. Acad. Sci. USA. 93: 9730-9735.										
7	EE	Hughes et al., 1981, "Characterization of plasma membrane proteins identified by monoclonal antibodies", J. of Biol./ Chem. 256(2): 664-671.										



Deliv ry: BY HAND

Sh et 2 f 2

· CY	EF	Isaacs et al., 1988, "Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha2-macroglobulin receptor recognition site", J. Biol. Chem. 263(14): 6709-6714.					
4	EG	Katsutani et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." Fundam Appl Toxicol.19(4):555-62.					
ct	ЕН	Kim et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.					
cY	EI	Kimber et al., 2002, "Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation." Biochem Cell Biol. 2002;80(1):103-7.					
cY	EJ	Moestrup et al., 1990, "Immunocytochemical identification of the human aplpha 2-macroglobulin receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte differentiation antigen", Exper. Cell Res. 190: 195-203.					
CY	EK	Opekun et al., 1999, "Novel therapies for Helicobacter pylori infection." Aliment Pharmacol Ther. 13(1):35-42.					
و٢	EL	Reed et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80.					
cY	ЕМ	Yamauchi et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.					
CY	EN	Zimecki et al., 1998, "Immunoregulatory effects of a nutritional preparation containing bovine lactoferrin taken orally by healthy individuals." Arch Immunol Ther Exp (Warsz). 46(4):231-40.					
d	EO	Zimecki et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.					
EXAMIN	EXAMINER Chrus ph HYC DATE CONSIDERED 5/23/02						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conference and not considered. Include copy of this form with next communication to applicant.